Istanbul Il Saglik Mudurlugu Goztepe Prof. Dr. Sul

Istanbul 34000

0 studies enrolling now · 2 studies all time

What they study most

PD-L1 Negative, PD-L1 Positive, Triple Negative Breast Cancer

Studies at this site

• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling